Cholesteryl ester transfer protein and atherosclerosis

Current Opinion in Lipidology

Volumn 11, Issue 4, 2000, Pages 389-396

  Inazu, Akihiro ^a   Koizumi, Junji ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PRAVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD LEVEL; DNA POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MOUSE; NONHUMAN; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ALLELES; ANIMALS; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; GENOTYPE; GLYCOPROTEINS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MICE; MICE, TRANSGENIC; MODELS, GENETIC; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC;

MUS MUSCULUS;

EID: 0033854319     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200008000-00008     Document Type: Review

References (55)

1. 1 Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinemia. Atherosclerosis 1985; 58:175-186.
2. 2 Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323:1234-1238.
3. 3 Bruce C, Tall AR. Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 1995; 6:306-311.
4. 4 Yamashita S, Sakai N, Hirano K, et al. Molecular genetics of plasma cholesteryl ester transfer protein. Curr Opin Lipidol 1997; 8:101-110.
5. 5 Mero N, van Toi A, Scheek LM, et al. Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normotipidemic smoking men: relations with lipid transfer proteins and LCAT activities. J Lipid Res 1998; 39:1493-1502.
6. 6 Kinoshita M, Teramoto T, Shimazu N, et al. CETP is a determinant of serum LDL-cholesterol but not HDL-cholesterol in healthy Japanese. Atherosclerosis 1996; 120:75-82.
7. 7 Dullaart RP, Hoogenberg K, Dikkeschei BD, van Tol A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994; 14:1581-1585.
8. r apoF, and showed LDL specificity and oleate sensitivity.
9. 9 Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 1999; 10:321-327.
10. 10 Jiang X, Bruce C, Mar J, et al. Targeted mutation of plasma phopholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103:907-914. PLTP knockout mice showed that low PLTP activity causes markedly decreased HDL levels, suggesting that the transfer of surface components of triglyceride-rich lipoproteins is essential to maintain HDL levels.
11. 11 Ruhling K, Lang A, Richard F, et al. Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. Metabolism 1999; 48:1361-1366. CET but not CETP mass was the best parameter to discriminate normolipidaemic patients with vascular disease from controls. Increased CET was positively correlated with triglyceride and PLTP activity, and negatively with specific CETP activity.
12. 12 Bagdade JD, Ritter MC, Subbaiah PV. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest 1991; 87:1259-1265.
13. 13 Pruneta V, Pulcini T, Lalanne F, et al. VLDL-bound lipoprotein lipase facilitates the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from HDL to VLDL. J Lipid Res 1999; 40:2333-2339. Severe lipoprotein lipase deficiency exhibited decreased net mass CET, in contrast with increased net CET in common hypertriglyceridaemia. Lipoprotein lipase had stimulating effects on CET even when lipolytic activity was totally blocked.
14. 14 Christison JK, Rye K-A, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995; 36:2017-2026.
15. 15 Sugano M, Sawada S, Tsuchida K, et al. Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J Lipid Res 2000; 41:126-133. By a monoclonal antibody against CETP, both the cholesteryl ester and triglyceride content in LDL was decreased. Monoclonal antibody-treated LDL became resistant against oxidation, which was assessed by thiobarbituric acid reactive substances or diene formation. These results suggest that low CETP plays an anti-atherogenic role in LDL remodelling.
16. 16 Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoproein cholesterol and apolipoprotein levels. Clin Genet 1989; 35:49-56.
17. 17 Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995; 96:1664-1671.
18. 18 Kuivenhoven JA, Jukema JW, Zwinderman AH, et al., for the Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis N Engl J Med 1998; 338:86-93.
19. 19 Durlach A, Clavel C, Girard-Globa A, Durlach V. Sex-dependent association of a genetic polymorphism of cholesteryl ester transfer protein with high-density lipoprotein cholesterol and macrovascular pathology in type II diabetic patients. J Clin Endocrinol Metab 1999; 84:3656-3659. CETP TaqlB polymorphism affects HDL-cholesterol levels and the prevalence of CHD in men, but not in women with type 2 diabetes.
20. 20 Dachet C, Poirier O, Cambien F, et al. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels. Role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000; 20:507-515.
21. 21 Bernard S, Moulin P, Lagrost L, et al. Association between plasma HDL-cholesterol concentration and TaqlB CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J Lipid Res 1998; 39:59-65.
22. 22 Kuivenhoven JA, de Knijff P, Boer JMA, et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997; 17:560-568.
23. 23 Riemens SC, van Tol A, Stulp BK, Dullaart RPF. Influence of insulin sensitivity and the TaqlB cholesteryl ester transfer protein gene polymorphism on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men. J Lipid Res 1999; 40:1467-1474.
24. 24 Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet 1999; 22:231-238.
25. 25 Cambien F, Poirier O, Nicaud V, et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet 1999; 65:183-191.
26. 26 Moriyama Y, Okamura T, Inazu A, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998; 27:659-667.
27. 27 Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997; 17:1053-1059.
28. 28 Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
29. 29 Kimura H, Gejyo F, Yamaguchi T, et al. A cholesteryl ester transfer protein gene mutation and vascular disease in dialysis patients. J Am Soc Nephrol 1999; 10:294-299.
30. 30 Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998; 39:1071-1078.
31. 31 Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerosis lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96:2071-2074.
32. 32 Gudnason V, Kakko S, Nicaud V, et al., on behalf of the EARS group. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. Eur J Clin Invest 1999; 29:116-128.
33. 33 Kakko S, Tamminen M, Paivansalo M, et al. Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men. Eur J Clin Invest 2000; 30:18-25. In 515 subjects with mild hypercholesterolaemia, decreased CETP levels associated with V405 polymorphism was a risk factor for carotid atherosclerosis. In contrast, higher CETP levels associated with Q451 were anti-atherogenic. There was an interaction of VV405 and alcohol intake or high triglyceride levels on atherosclerosis.
34. 34 Inazu A, Jiang X-C, Haraki T, et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 1994; 94:1872-1882.
35. 35 Guerin M, Dolphin PJ, Talussot C, et al. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15:1359-1368.
36. 36 Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis 1998; 141:87-98.
37. 37 Inazu A, Koizumi J, Kajinami K, et al. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 1999; 145:405-413.
38. 38 Guerin M, Lassel TS, Le Goff W, et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20:189-197.
39. 39 Chouinard Jr RA, Luo Y, Osborne TF, et al. Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vitro but is not required for sterol up-regulation of gene expression. J Biol Chem 1998; 273:22409-22414.
40. 40 Gauthier B, Robb M, Gaudet F, et al. Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: functional role of the transcription factors SREBP-1a, -2, and YY1. J Lipid Res 1999; 40:1284-1293.
41. 41 Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000; 105:513-520.
42. 42 Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364:73-75.
43. 43 Plump AS, Masucci-Magoulas L, Bruce C, et al. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19:1105-1110. CETP was a pro-atherogenic factor in apoE knockout and LDL receptor knockout mice. However, this pro-atherogenicity appears to be weaker than anti-atherogenic effects of apoAI transgene in apoE knockout/apoAI/CETP mice.
44. 45 Herrera VLM, Makrides SC, Xie HX, et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nature Med 1999; 5:1383-1389.
45. 46 Cheung MC, Wolfbauer G, Albers JJ. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta 1996; 1303:103-110.
46. 47 Sugano M, Makino N, Sawada S, et al. Effects of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998; 273:5033-5036.
47. 48 Sawada S, Sugano M, Makino N, et al. Secretion of prebeta HDL increases with the suppression of cholesteryl ester transfer protein in Hep G2 cells. Atherosclerosis 1999; 146:291-298.
48. 49 Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991; 88:2059-2066.
49. 50 Sich D, Saidi Y, Giral P, et al. Hyperalphalipoproteinemia: characterization of a cardioprotective profile associating increased high-density lipoprotein2 levels and decreased hepatic lipase activity. Metabolism 1998; 47:965-973.
50. 51 Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029-1036.
51. 52 Francone OL, Royer L, Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res 1996; 37:1268-1277.
52. 53 Oliveira HCF, Ma L, Milne R, et al. Cholesteryl ester transfer protein (CETP) activity enhances plasma cholesteryl ester formation: studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol 1997; 17:1045-1052.
53. 54 Collet X, Tall AR, Serajuddin H, et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL cholesteryl ester by cells expressing scavenger receptor B-I. J Lipid Res 1999; 40:1185-1193. Uptake of HDL-cholesteryl ester by SRBI is a major route for RCT. Both CETP and hepatic lipase participate in remodelling HDL, resulting in enhanced cholesteryl ester transport to the liver via SRBI, suggesting an anti-atherogenic role of CETP in this pathway.
54. 55 Hirano K, Yamashita S, Kuga Y, et al. Atherosclerotic disease in marked hyperalphalipoproeinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 1995; 15:1849-1856.
55. 56 Dullaart RPF, Hoogenberg K, Riemens SC, et al. Cholesteryl ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid-lowering diet in Type 1 diabetes. Diabetes 1997; 46:2082-2087.